When was PreludeDx founded?

PreludeDx was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is PreludeDx located?

PreludeDx is headquartered in Laguna Hills, United States.

How many employees does PreludeDx have?

As of Mar 31, 2026, the latest employee count at PreludeDx is 93.

Is PreludeDx a funded company?

PreludeDx is a funded company, having raised a total of $51.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 15, 2016.

When was the latest funding round of PreludeDx?

PreludeDx's latest funding was a $***** Series B round on Oct 30, 2025, with participation from 0 investor.

Where does PreludeDx rank among its competitors?

PreludeDx ranks 2nd amongst 97 active competitors, of which 40 are funded. It stands 1st in terms of total funding among its competitors.

Who are the top competitors of PreludeDx?

PreludeDx's top competitors include ScreenPoint, Raysearch laboratories and Syantra. Among them, PreludeDx secured the most recent funding round in October, 2025.

PreludeDx - 2026 Company Profile, Funding & Competitors

Company Details

Provider of risk assessment tests for early-stage breast cancer. The flagship product DCISionRT is targeted at patients who have breast cancer staged at ductal carcinoma in situ (DCIS). The company uses a panel of disease-associated biomarkers and proprietary algorithms to classify DCIS patients into high-risk and low-risk categories. The system has features for predicting the treatment for cancer patients as well.

Website: preludedx.com
Email ID: *****@preludedx.com

Key Metrics

Founded Year

2009

Location

Laguna Hills, United States

Stage

Series B

Total Funding

$51.7M in 7 rounds

Latest Funding Round

Series B, Oct 30, 2025, $*****

Investors

Evidity Health Capital & 2 more

Ranked

2^nd among 97 active competitors

Employee Count

93 as on Mar 31, 2026

Similar Companies

ScreenPoint & 135 more

View PreludeDx's full profile

PreludeDx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Prelude Corporation CIN: 90-0495385 , United States, Active	May 12, 2009	-	33 (As on Dec 31, 2021)	-

PreludeDx has raised a total funding of $51.7M over 7 rounds. Its first funding round was on Mar 15, 2016. PreludeDx has 3 institutional investors.

Here is the list of recent funding rounds of PreludeDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2025	9126796	Series B	5786411	2991803	5490943	9403400
Mar 22, 2022	9597275	Series B	8199304	9725278	6906479	6223005
Jul 20, 2021	5671362	Series B	8998315	9953086	GenesisCare	2368462

Access funding benchmarks and valuations. Sign up today!

View details of PreludeDx's funding rounds and investors

PreludeDx's employee count trend

PreludeDx has 93 employees as of Mar 26. Here is PreludeDx's employee count trend over the years:

Uncover PreludeDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PreludeDx include ScreenPoint, Raysearch laboratories and Syantra. Here is the list of Top 10 competitors of PreludeDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Provider of AI-based medical image analysis systems	$33M	Insight Partners, Siemens & 3 others	55/100
2nd	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Fjord Ventures, Evidity Health Capital & 1 others	57/100
3rd	Raysearch laboratories 2000, Stockholm (Sweden), Public	Cloud-based radiation therapy software for oncology professionals	-	Quinary Investment, Corda Campus & 1 others	50/100
4th	Syantra 2013, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Canaccord Genuity Group, Plug and Play Tech Center ... & 4 others	48/100
5th	Koning 2002, Henrietta (United States), Funding Raised	Develops and markets early breast cancer detection tool	-	Dingxin Capital, Excell Partners & 1 others	47/100
6th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100
7th	Miltel 2012, Hiroshima (Japan), Series A	Provider of telomere test for detection of aging	$5.28M	Ntt Docomo Ventures, UTEC & 4 others	45/100
8th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	-	44/100
9th	Predilife 2004, Villejuif (France), Public	Provider of personalized breast screening	-	-	43/100
10th	POC Medical Systems 2013, Livermore (United States), Deadpooled	Point of care testing product for Breast Cancer	$22.1M	VI Ventures, BioVentures Investors & 8 others	41/100